Eli Lilly ends partnership with Foghorn Therapeutics, prompting 40% staff cut at biotech

Eli Lilly announced it is withdrawing from its collaboration with Foghorn Therapeutics on a synthetic lethality drug program.

Following the pullback, Foghorn said it will cut roughly 40% of its workforce, reflecting the loss of the partnership.

The termination reduces Foghorn’s development capacity and highlights the challenges of advancing synthetic lethality projects in the current environment.